• Disease Areas
    • Diabetes
    • Obesity
    • Cardiovascular Disease (CVD)
    • Chronic Kidney Disease (CKD)
    • Metabolic Dysfunction-Associated Steatohepatitis (MASH)
    • Neurodegenerative Diseases
    • Haemophilia
    • Sickle Cell Disease
    • Primary Hyperoxaluria
    • Growth Hormone Disorders
    • Hormone Replacement Therapy
  • Congresses
  • Scientific Publications
  • IME

Register Login
My Account
Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

  • Congresses
  • 31st European Congress on Obesity
  • STEP 10 trial: semaglutide 2.4 mg provided a superior reduction vs placebo in body weight and reversion to normoglycaemia in participants with obesity and prediabetes
31st European Congress on Obesity